Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02757859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Apr 27, 2026 to Aug 2028v16 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 2 to 1
    • Study completion date: Apr 27, 2026 to May 2031
    • Secondary endpoints: 4 to 3
    • Study description expanded, about 207 words
    • Study title shortened, about 12 words
    • Eligibility criteria shortened, about 3 words
  2. Re-verified, no change to tracked fieldsv15
  3. Primary completion date: Apr 2024 to Apr 27, 2026
    • Study completion date: Jan 2025 to Apr 27, 2026
    • Eligibility criteria expanded, about 23 words
    v14
  4. Phase: Phase 3 to Not applicable
    • Collaborators shortened, about 4 words
    v13
  5. Phase: Not applicable to Phase 3v12
Show 10 earlier versionsHide 10 earlier versions
  1. Enrollment target: 667 to 845v11 Show 5 more changesShow less
    • Interventions: Lavage (Other), Pancreatectomy (Procedure) to Lavage (Other), Lavage (Other), Pancreatectomy (Procedure), Pancreatectomy (Procedure), Pancreatectomy (Procedure)
    • Eligibility criteria expanded, about 70 words
    • Study description shortened, about 11 words
    • Site details revised at 2 of 2 sites
    • Collaborators expanded, about 4 words
  2. Primary completion date: Apr 2022 to Apr 2024
    • Study completion date: Jan 2023 to Jan 2025
    v10
  3. Primary completion date: Aug 2021 to Apr 2022
    • Study completion date: Jan 2022 to Jan 2023
    v9
  4. Primary completion date: Aug 2020 to Aug 2021
    • Study completion date: Jan 2021 to Jan 2022
    v8
  5. Re-verified, no change to tracked fieldsv7
  6. Study sites: 1 to 2v6
  7. Re-verified, no change to tracked fieldsv5
  8. Start date: Feb 2016 to Apr 27, 2016
    • Study completion date: Jan 2021
    • Study site revised
    v4
  9. Lead sponsor: Thomas Jefferson University to Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universityv3
  10. Study description expanded, about 11 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if a special washing treatment used during surgery can help people with pancreatic cancer live longer. The study includes adults who are having surgery for suspected pancreatic cancer or related cancers in nearby organs (called periampullary cancers). The main questions it aims to answer are: * Does the washing treatment improve overall survival (how long patients live)? * Does it improve how long patients remain cancer-free and reduce cancer recurrence or complications? The investigators will compare two types of washing treatments and standard care to see if either method improves outcomes. Participants will: Be assigned by chance (randomized) before surgery to one of three groups: * Washing with warm saltwater (saline) * Washing with sterile water * No extensive washing (standard care) Undergo their planned cancer surgery, during which the washing treatment (if assigned) will be performed right after the tumor is removed Be followed over time to monitor survival, cancer recurrence, and any side effects The investigators estimate the washing treatment could increase average survival from about 18 months to 27 months. To ensure enough patients with confirmed pancreatic cancer are included, about 845 participants will be enrolled over time.
Trial Details
NCT Number NCT02757859
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Conditions
(from sponsor)		 Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Periampullary Adenocarcinoma
Related terms Carcinoma, Acinar Cell, Cholangiocarcinoma, Pancreatic Intraductal Neoplasms
Enrollment 845 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov